Abstract
To date, inborn errors of neurotransmitters have been defined based on the classic concept of inborn error of metabolism (IEM), and they include defects in synthesis, catabolism, and transport pathways. However, the omics era is bringing insights into new diseases and is leading to an extended definition of IEM including new categories and mechanisms. Neurotransmission takes place at the synapse, the most specialized tight junction in the brain. The concept of “synaptic metabolism” would point to the specific chemical composition and metabolic functions of the synapse. Based on these specialized functions, we aim to provide a tentative overview about the major categories of IEM susceptible to affect neurotransmission. Small molecule defects (biogenic amines and amino acids) and energy defects are amongst the most prevalent diseases reported to disturb the concentration of CSF neurotransmitters. In these IEM, the neurological phenotypes have been largely described. Disorders of complex molecules are not typically considered as diseases affecting neurotransmission. However, most of them have been recently discovered and are involved in intracellular vesiculation, trafficking, processing, and quality control mechanisms. In this large group, neurotransmission is affected in disorders of chaperones and autophagy, disorders of the synaptic vesicle, and diseases affecting pre-synaptic membranes (synthesis and remodeling of complex lipids, defects of glycosylation). Disorders of the vesicle pools, receptor trafficking, and the chronobiology of neurotransmission are potentially emerging new categories. Finally, although not considered as IEM, channelopathies are a large group of diseases disturbing neurotransmitter homeostasis. New CSF biomarkers will probably contribute to improve the diagnosis of these disorders and find new therapeutic targets.
Similar content being viewed by others
References
Anggono V and Huganir RL (2012) Regulation of AMPA receptor trafficking and synaptic plasticity. Curr Opin Neurobiol 22(3):461–69
Anikster Y, Tobias BH, Thierry V, Pode-Shakked B, Thöny B, Shen N, Guarani V et al (2017) Biallelic mutations in DNAJC12 cause hyperphenylalaninemia, dystonia, and intellectual disability. Am J Hum Genet 100(2):257–266. https://doi.org/10.1016/j.ajhg.2017.01.002
Appenzeller S, Balling R, Barisic N, Baulac S, Caglayan H, Craiu D, De Jonghe P et al (2014) De novo mutations in synaptic transmission genes including DNM1 cause epileptic Encephalopathies. Am J Hum Genet 100(1):179. https://doi.org/10.1016/j.ajhg.2016.12.012.
Bonafé L, Thöny B, Penzien JM, Czarnecki B, Blau N (2001) Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 69(2):269–277. https://doi.org/10.1086/321970
Cortès-Saladelafont E, Molero-Luis M, Ormazábal A, Tristán-Noguero A, Díez H, Sierra C, Armstrong J, Artuch R, Garcia-Cazorla A (2015) Diagnosis of biogenic amines synthesis defects. pdf. J Pediatr Neurol 13:186–197
Cortès-Saladelafont E, Tristán-Noguero A, Artuch R, Altafaj X, Bayès A, García-Cazorla A (2016) Diseases of the synaptic vesicle: a potential new group of neurometabolic disorders affecting neurotransmission. Semin Pediatr Neurol 23(4):306–320
Curtis RC, Hyland K, Ficicioglu CF, Randall R (2012) Dihydropteridine reductase deficiency and treatment with tetrahydrobiopterin: a case report. JIMD Reports 4:113–116. https://doi.org/10.1007/8904.
Deas E, Plun-Favreau H, Wood NW (2009) PINK1 function in health and disease. EMBO Molecular Medicine 1(3):152–165. https://doi.org/10.1002/emmm.200900024
De Grandis E, Serrano M, Pérez-Dueñas B, Ormazábal A, Montero R, Veneselli E, Pineda M et al (2010) Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders. J Inherit Metab Dis 33(6):803–809. https://doi.org/10.1007/s10545-010-9200-9
Dick KJ, Eckhardt M, Paisán-Ruiz C, Alshehhi AA, Proukakis C, Sibtain NA, Maier H et al (2010) Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum Mutat 31(4):1251–1260. https://doi.org/10.1002/humu.21205.
Díez H, Cortès-Saladelafont E, Ormazábal A, Fernández Marmiese A, Armstrong J, Matalonga L, Bravo M et al (2017) Severe infantile Parkinsonism because of a de novo mutation on DLP1 mitochondrial-peroxisomal protein. Mov Disord 32(7):1108–1110. https://doi.org/10.1002/mds.27021
Galanopoulou AS (2010) Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch 460:505–523. https://doi.org/10.1007/s00424-010-0816-2
Garcia-Cazorla A, Duarte S, Serrano M, Nascimento A, Ormazabal A, Carrilho I, Briones P et al (2008) Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 8(3):273–278. https://doi.org/10.1016/j.mito.2008.05.001
García-Cazorla A, Saudubray JM (2018) Cellular neurometabolism: a tentative to connect cell biology and metabolism in neurology. J Inherit Metab Dis (In Press)
Geldenhuys WJ, Abdelmagid SM, Gallegos PJ, Safadi FF (2014) Parkinson’s disease biomarker: a patent evaluation of WO2013153386. Expert Opinion Therapeutic Patents 24(8):947–951. https://doi.org/10.1517/13543776.2014.931375
Gozes I, Van Dijck A, Hacohen-Kleiman G, Grigg I, Karmon G, Giladi E, Eger M et al. (2017). Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children. Translational Psychiatry 7 (2). Nature Publishing Group. doi:10.1038/tp.2017.27.
Henderson MX, Wirak GS, Zhang YQ, Dai F, Ginsberg SD, Dolzhanskaya N, Staropol JF et al (2016) Neuronal ceroid lipofuscinosis with DNAJC5/CSP mutations have PPT1 pathology and exhibit aberrant protein palmitoylation. Acta Neuropathol 131(6188):621–637. https://doi.org/10.1126/science.1249098.
Horvath GA, Demos M, Shyr C, Matthews A, Zhang L, Race S, Stockler-Ipsiroglu S et al (2016) Secondary neurotransmitter deficiencies in epilepsy caused by voltage-gated sodium channelopathies: a potential treatment target? Mol Genet Metab 117(1). Elsevier Inc):42–48. https://doi.org/10.1016/j.ymgme.2015.11.008
Hu Z, Tong XJ, Kaplan JM (2013) UNC-13L, UNC-13S, and tomosyn form a protein code for fast and slow neurotransmitter release in Caenorhabditis elegans. ELife 2:1–20. https://doi.org/10.7554/eLife.00967
Klein C, Westenberger A (2012) Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 30(6):386–396. https://doi.org/10.1016/j.mcp.2016.11.001.
Krebs CE, Karkheiran S, Powell JC, Cao M, Makarov V, Darvish H, Di Paolo G et al (2013) The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum Mutat 34(9):1200–1207. https://doi.org/10.1146/annurev-cellbio-092910-154240.Sensory.
Kumar A, Dejanovic B, Hetsch F et al (2017) S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenumcofactor deficiency. J Clin Invest 127(12):4365–4378
Kurian MA, Zhen J, Cheng SY, Li Y, Mordekar SR, Jardine P, Morgan NV et al (2009) Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile Parkinsonism-dystonia. Children 119(6):1595–1603. https://doi.org/10.1172/JCI39060.tigations
Kurolap A, Armbruster A, Hershkovitz T et al (2016) Loss of glycine transporter 1 causes a subtype of glycine encephalopathy with arthrogryposis and mildly elevated cerebrospinal fluid glycine. Am J Hum Genet 99:1172–1180
Lauwers E, Goodchild R, Verstreken P (2016) Membrane lipids in presynaptic function and disease. Neuron 90(1). Elsevier Inc):11–25. https://doi.org/10.1016/j.neuron.2016.02.033
Leuzzi V, Carducci CA, Carducci CL, Pozzessere S, Burlina A, Cerone R, Concolino D et al (2010) Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency. Clin Genet 77(3):249–257. https://doi.org/10.1111/j.1399-0004.2009.01306.x
Madeo M, Stewart M, Sun Y, Sahir N, Wiethoff S, Chandrasekar I, Yarrow A et al (2016) Loss-of-function mutations in FRRS1L lead to an epileptic-dyskinetic encephalopathy. Am J Hum Genet 98:1249–1255. https://doi.org/10.1016/j.ajhg.2016.04.008
Manegold C, Hoffmann GF, Degen I, Ikonomidou H, Knust A, Laaß MW, Pritsch M et al (2009) Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis 32(3):371–380. https://doi.org/10.1007/s10545-009-1076-1
Marecos C, Ng J, Kurian MA (2014) What is new for monoamine neurotransmitter disorders? J Inherit Metab Dis 37(4):619–626. https://doi.org/10.1007/s10545-014-9697-4
Molero-Luis M, Serrano M, Ormazábal A, Pérez-Dueñas B, García-Cazorla A, Pons R, Artuch R (2013) Homovanillic acid in cerebrospinal fluid of 1388 children with neurological disorders. Dev Med Child Neurol 55(6):559–566. https://doi.org/10.1111/dmcn.12116
Neher, Erwin. (2015). Merits and limitations of vesicle pool models in view of heterogeneous populations of synaptic vesicles.” Neuron 87 (6). Elsevier: 1131–42. doi:10.1016/j.neuron.2015.08.038.
Ng J, Papandreou A, Heales SJ, Kurian MA (2015) Monoamine neurotransmitter disorders—clinical advances and future perspectives. Nat Rev Neurol 11(10). Nature Publishing Group):567–584. https://doi.org/10.1038/nrneurol.2015.172
Olgiati S, Quadri M, Fang M, Rood JP, Saute JA, Chien HF, Bouwkamp CG et al (2016) DNAJC6 mutations associated with early-onset Parkinson’s disease. Ann Neurol 79(2):244–256. https://doi.org/10.1002/ana.24553.
Opladen T, Hoffmann G, Hörster F, Hinz AB, Neidhardt K, Klein C, Wolf N (2011) Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord 26(1):138–141. https://doi.org/10.1002/mds.23301.
Pearl PL, Taylor JL, Trzcinski S, Sokohl A (2007) The pediatric neurotransmitter disorders. J Child Neurol 22(5):606–616. https://doi.org/10.1177/0883073807302619
Pearl PL, Parviz M, Vogel K, Schreiber J, Theodore WH, Gibson KM (2014) Inherited disorders of gamma-aminobutyric acid metabolism and advances in ALDH5A1 mutation identification. Dev Med Child Neurol 57(7):611–617. https://doi.org/10.1111/dmcn.12668
Pegg AE (2014) The function of spermine. IUBMB Life 66(1):8–18. https://doi.org/10.1002/iub.1237
Petrov AM, Kasimov MR, Zefirov AL (2016) Brain cholesterol metabolism and its defects: linkage to neurodegenerative diseases and synaptic dysfunction. Acta Nat 8(1):58–73
Rempe T, Kuhlenbäumer G, Krüger S, Biskup S, Matschke J, Hagel C, Deuschl G, Van Eimeren T (2016) Early-onset Parkinsonism due to compound heterozygous POLG mutations. Parkinsonism Related Disorders 29:135–137. https://doi.org/10.1016/j.parkreldis.2016.04.020
Rilstone JJ, Alkhater RA, Minassian BA (2013) Brain dopamine–serotonin vesicular transport disease and its treatment. N Engl J Med 368(6):543–550. https://doi.org/10.1056/NEJMoa1207281
Scott H, Panin VM (2014) The role of protein N-glycosylation in neural transmission. Glycobiology 24(5):407–417. https://doi.org/10.1093/glycob/cwu015
Senard JM, Rouet P (2006) Dopamine beta-hydroxylase deficiency. Orphanet J Rare Diseases 1(1):1–4. https://doi.org/10.1186/1750-1172-1-7.
Sjaastad O, Berstad J, Gjesdahl P, Gjessing L (1976) Homocarnosinosis. 2. A familial meta-bolic disorder associated with spastic paraplegia, progressive mental deficiency, and retinal pigmentation. Acta Neurol Scand 53:275–290. https://doi.org/10.1111/j.1600-0404.1976.tb04348.x
Soto D, Altafaj X, Sindreu C, Bayés A (2014) Glutamate receptor mutations in psychiatric and neurodevelopmental disorders. Commun Integr Biol 7(1):e27887. https://doi.org/10.4161/cib.27887
Spillane J, Kullmann DM, Hanna MG (2016) Genetic neurological channelopathies: molecular genetics and clinical phenotypes. J Neurol Neurosurg Psychiatry 87(1):37–48. https://doi.org/10.1136/jnnp-2015-311233.
Südhof TC (2013) Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron 80(3). https://doi.org/10.1016/j.neuron.2013.10.022.N
Südhof TC (2017) Molecular neuroscience in the 21st century: a personal perspective. Neuron 96(3):536–541. https://doi.org/10.1016/j.neuron.2017.10.005
Tada K, Hayasaka K (1987) Non-ketotic hyperglycinaemia: clinical and biochemical aspects. Europ J Pediat 146:221–227
Takada Y, Sakai Y, Matsushita Y, Ohkubo K, Koga Y, Akamine S, Torio M et al (2017) Sustained endocrine profiles of a girl with WAGR syndrome. BMC Medical Genetics 18(1):1–5. https://doi.org/10.1186/s12881-017-0477-5
Thibodeau ML, Peters CH, Townsend KN, Shen Y, Hendson G, Adam S, Selby K et al (2017) Compound heterozygous TRPV4 mutations in two siblings with a complex phenotype including severe intellectual disability and neuropathy. American J Medical Genetics, Part A 173(11):3087–3092. https://doi.org/10.1002/ajmg.a.38400
Tijssen MAJ & Rees MI. Hyperekplexia (1993-2018) GeneReviews. Seattle (WA): University of Washington, Seattle
Tsuji M, Aida N, Obata T, Tomiyasu M, Furuya N, Kurosawa K, Errami A et al (2010) A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy. J Inherit Metab Dis 33:85–90. https://doi.org/10.1007/s10545-009-9022-9
Wei S, Soh SL, Xia J, Ong WY, Pang ZP, Han W (2014) Motor neuropathy-associated mutation impairs seipin functions in neurotransmission. J Neurochem 129(2):328–338. https://doi.org/10.1111/jnc.12638
Willemsen MA, Verbeek MM, Kamsteeg EJ, de Rijk-van Andel JF, Aeby A, Blau N, Burlina A et al (2010) Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain: A Journal of Neurology 133(Pt 6):1810–1822. https://doi.org/10.1093/brain/awq087
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This article does not contain any studies with human or animal subjects performed by any of the authors.
Conflict of interest
A. Tristán-Noguero and À. García-Cazorla declare that they have no conflict of interest.
Informed consent
Not applicable.
Animal rights
Not applicable.
Additional information
Communicating Editor: Nenad Blau
Rights and permissions
About this article
Cite this article
Tristán-Noguero, A., García-Cazorla, À. Synaptic metabolism: a new approach to inborn errors of neurotransmission. J Inherit Metab Dis 41, 1065–1075 (2018). https://doi.org/10.1007/s10545-018-0235-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-018-0235-7